Skip to content
type1.science
Phase 2Active, not recruitingNCT05683990

Diamyd GAD-alum in people at risk for T1D

Phase 2 feasibility/safety study of Diamyd antigen-specific immunotherapy in individuals at risk for type 1 diabetes.

Primary endpoints

  • Occurrence of AEs (including Injection site reactions) and SAEs
  • Number of Clinically Significant Abnormal Results from Physical examinations, including neurological and Vital Signs assessments
  • Number of Clinically Significant Abnormal Results From Laboratory measurements, including hematology, clinical chemistry, metabolic status parameters (fasting C-peptide, HbA1c, fasting glucose) and urine analysis

Results so far

No results posted yet.